PDF(Pubmed)
Abstract：
The majority of patients with thyroid cancer can attain a favorable prognosis with a comprehensive treatment program based on surgical treatment. However, the current treatment options for advanced thyroid cancer are still limited. In recent years, chimeric antigen receptor-modified T-cell (CAR-T) therapy has received widespread attention in the field of oncology treatment. It has achieved remarkable results in the treatment of hematologic tumors. However, due to the constraints of multiple factors, the therapeutic efficacy of CAR-T therapy for solid tumors, including thyroid cancer, has not yet met expectations. This review outlines the fundamental structure and treatment strategies of CAR-T cells, provides an overview of the advancements in both preclinical investigations and clinical trials focusing on targets associated with CAR-T cell therapy in treating thyroid cancer, and discusses the challenges and solutions to CAR-T cell therapy for thyroid cancer. In conclusion, CAR-T cell therapy is a promising therapeutic approach for thyroid cancer, and we hope that our review will provide a timely and updated study of CAR-T cell therapy for thyroid cancer to advance the field.
摘要：
大多数甲状腺癌患者可以通过基于手术治疗的综合治疗方案获得良好的预后。然而,目前晚期甲状腺癌的治疗选择仍然有限.近年来,嵌合抗原受体修饰T细胞(CAR-T)治疗在肿瘤治疗领域受到广泛关注。在血液肿瘤的治疗中取得了显著的效果。然而,由于多种因素的制约，CAR-T治疗实体肿瘤的疗效，包括甲状腺癌,尚未达到预期。本文概述了CAR-T细胞的基本结构和治疗策略。概述了临床前研究和临床试验的进展，重点是与CAR-T细胞疗法治疗甲状腺癌相关的靶标，并讨论了CAR-T细胞治疗甲状腺癌的挑战和解决方案。总之,CAR-T细胞疗法是甲状腺癌的一种有前途的治疗方法，我们希望我们的审查将提供及时和更新的CAR-T细胞治疗甲状腺癌的研究，以推进该领域。
